Due to its more restricted expression compared with other CSC markers such as CD44 and aldehyde dehydrogenase (ALDH), CD133 has long been considered the most rigorous indicator of malignant precursors in different solid tumors, including breast cancer [14]. This evidence concerns the gene CD44 and breast cancer.